ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon & Dr. Jorge Garcia

What's New in Endometrial Cancer: Key Takeaways From SGO 2026

Join Scott E. Jordan, MD, FACOG, gynecologic oncologist at Broward Health, as he breaks down the most important endometrial cancer updates presented at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting. In this episode, Dr. Jordan reviews promising new therapies, including emerging antibody-drug conjugates and novel hormonal treatment combinations, highlights exciting clinical trial results, and discusses long-term follow-up data from the practice-changing RUBY trial. From breakthrough research to upcoming Phase III studies that may shape the future standard of care, this conversation provides oncology professionals with key insights into the rapidly evolving treatment landscape for advanced and recurrent endometrial cancer.

ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon & Dr. Jorge Garcia

What does it take to successfully navigate the business of oncology while continuing to deliver exceptional patient care? In this episode of the FLASCO OncoPod, Dr. Robin Zon joins Dr. Jorge Garcia for a thoughtful conversation about leadership, advocacy, and the launch of ASCO Edge, a new educational resource designed to help oncology professionals better understand the operational and business side of cancer care. Dr. Zon reflects on her professional journey from community oncology practice to serving as President of ASCO, sharing how early experiences shaped her passion for empowering clinicians with the tools needed to manage practices, navigate evolving healthcare systems, and advocate for both patients and providers. Together, they explore: • The inspiration behind ASCO Edge • Why business education matters in oncology • Challenges facing modern cancer care delivery • How oncology professionals can strengthen operational knowledge • The importance of state societies and collaborative advocacy • What clinicians, pharmacists, APPs, fellows, and practice leaders can gain from the platform Designed by oncology professionals for oncology professionals, ASCO Edge offers practical, on-demand learning modules focused on real-world scenarios impacting cancer care today. Learn more about FLASCO and upcoming educational initiatives at FLASCO.org [http://FLASCO.org] Get started with ASCO Edge today at https://www.asco.org/meetings-education/training-programs/asco-edge [https://www.asco.org/meetings-education/training-programs/asco-edge] #FLASCO #Oncology #ASCO #CancerCare #CommunityOncology #HealthcareLeadership #MedicalEducation #OncoPod #OncologyPodcast #PracticeManagement #CancerResearch #OncologyProfessionals

"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 3: Genetics, Duration of Therapy, and Real-World Pearls

In this final episode of the FLASCO OncoPod series, Drs. Jaglal, Fu, and Shahzad shift focus to the long-term management of atypical hemolytic uremic syndrome (aHUS) in oncology patients. Building on the diagnostic and acute management discussions from earlier segments, the panel explores key considerations that guide care beyond the initial presentation. Topics include the role of genetic and complement testing, how to interpret mutation findings, and the factors that influence decisions around the duration of complement inhibition therapy. Through real-world insights, the discussion highlights the complexity of identifying underlying triggers, including drug exposure and infection, and the importance of clinical judgment when determining whether and when treatment can be safely discontinued. The panel also addresses practical challenges, from variability in testing access to navigating uncertainty in cases without clear pathogenic mutations. Listen as the experts walk through how thoughtful, individualized decision-making can support recovery, preserve renal function, and optimize long-term outcomes for patients with aHUS.

"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 2: Acute Management: TTP vs aHUS and Treatment Decisions

In this episode of the FLASCO OncoPod, Drs. Jaglal, Fu, and Shahzad explore the real-world challenges of managing suspected thrombotic microangiopathy (TMA) in oncology patients. Building on a complex multiple myeloma case introduced in Part 1, this segment focuses on acute decision-making in the hospital setting. The discussion highlights how to differentiate thrombotic thrombocytopenic purpura (TTP) from atypical hemolytic uremic syndrome (aHUS), when to initiate plasma exchange, and how clinicians approach complement inhibition in time-sensitive, high-stakes scenarios. Through expert insights and practical considerations, the panel walks through key diagnostic clues including peripheral smear findings, LDH elevation, and clinical presentation, while also addressing the realities of delayed lab results, treatment access, and institutional protocols. Listen in as they unpack how to act quickly, think critically, and navigate uncertainty to optimize outcomes in patients with suspected TMA.

"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 1: When to Suspect aHUS in Oncology Patients

Atypical hemolytic uremic syndrome (aHUS) in patients with malignancy or undergoing cancer-directed therapy is likely under-recognized, yet early identification can have a profound impact on patient outcomes. In this FLASCO OncoPod roundtable, Drs. Jaglal, Fu, and Shahzad examine the clinical realities of drug-induced and malignancy-associated aHUS, emphasizing the importance of maintaining a high index of suspicion in complex oncology cases. Through expert insight and real-world experience, they explore how subtle changes in laboratory values and clinical presentation can signal a more serious underlying process. In this first segment, the discussion centers on when to suspect aHUS in oncology patients, guided by an illustrative case that brings the diagnostic challenge into focus. The faculty highlight key warning signs, including evolving anemia, thrombocytopenia, and renal dysfunction, and underscore how timely recognition can significantly influence both renal recovery and overall patient trajectory.